Abstract 897P
Background
The early response to concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) is closely correlated with prognosis. In this study, we aimed to predict early response using a combined model that combines sub-regional radiomics features from multi-sequence MRI with clinically relevant factors.
Methods
A total of 104 patients with LA-NPC were randomly divided into training and validation cohorts at a ratio of 3:1. Radiomic features were extracted from subregions within the tumor area using the K-means clustering method, and feature selection was performed using LASSO regression. Four models were established: classical radiomics model, clinical medol, Intratumor Heterogeneity (ITH) score-based model and a fusion model combining ITH score with clinical factors. The predictive performance of these models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).
Results
Among the models, the combined model incorporating ITH score and clinical factors demonstrated the highest predictive performance in the test cohort (AUC = 0.838). Additionally, the models based on ITH score showed superior prognostic value in both the training cohort (AUC = 0.888) and the test cohort (AUC = 0.833).
Conclusions
The combined model that integrates the ITH score with clinical factors exhibited superior performance in predicting early response following concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
Clinical trial identification
Editorial acknowledgement
The authors would like to thank Yuandong Cao, Weilin Xu, and Shu Zhou for their valuable comments and discussions. We also express their gratitude to Jinling Yuan and Mengxing Wu for their assistance with data analysis. This work was supported by the Jiangsu Province Doctoral Start-up Foundation for Entrepreneurship and Innovation (Grant No. 2019303073386ER19) and the Clinical Competence Enhancement Project of Jiangsu Provincial People's Hospital (Grant No. JSPH-MC-2021-17).
Legal entity responsible for the study
The First Affiliated Hospital of Nanjing Medical University.
Funding
Jiangsu Province Entrepreneurship and Innovation Doctoral Talent Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
890P - Stereotactic body radiation therapy combined with chemotherapy and tislelizumab in metastatic nasopharyngeal carcinoma: A prospective, single-arm, phase II study
Presenter: Tongxin Liu
Session: Poster session 02
891P - Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer: The POINT study
Presenter: Cristina Gurizzan
Session: Poster session 02
892P - Camrelizumab plus dalpiciclib in anti-PD-1 refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Xi Ding
Session: Poster session 02
894P - AXEL: AXitinib-avELumab combination in recurrent or metastatic (RM) nasopharyngeal cancer (NPC)
Presenter: Edwin Hui
Session: Poster session 02
895P - Cost effectiveness of stereotactic ablative radiotherapy (SABR) alone in comparison with systemic treatment and SABR in oligometastatic head and neck cancer in the GORTEC 2014-04 OMET randomized phase II study
Presenter: Juliette Thariat
Session: Poster session 02
896P - Day of the week of chemotherapy (CT) during concurrent chemoradiation (CRT) for oropharyngeal squamous cell carcinoma (OPSCC)
Presenter: Camilla Hoff
Session: Poster session 02
898P - Real-world overall survival (OS) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) in Asia: A literature review
Presenter: Darren Wan-Teck Lim
Session: Poster session 02
899P - Safety and efficacy of a novel CAR-T cell therapy (BRG01) targeting the Epstein-Barr Virus envelope glycoprotein in advanced metastatic nasopharyngeal cancer patients
Presenter: Li Zhang
Session: Poster session 02